IBJNews

Lilly, Roche drugs chosen for Alzheimer’s prevention trial

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly & Co.’s solanezumab and Roche Holding AG’s gantenerumab were selected for a long-term Alzheimer’s trial run by Washington University at St. Louis scientists seeking to block the disease’s symptoms.

The experimental medicines will be tested in a trial called DIAN TU involving 160 people with a mutation that guarantees they will develop Alzheimer’s at an early age, perhaps as young as 30, the university said in a statement Wednesday.

If the trial is successful, it may lead to those drugs being widely used for people who may have a family history of the disease. Solanezumab slowed the decline in some patients with mild Alzheimer’s and provided no benefit to more advanced patients, Indianapolis-based Lilly announced in August. On Oct. 8, an independent group of scientists confirmed the findings.

“Trying to prevent Alzheimer’s symptoms from ever occurring is a new strategy,” said John C. Morris, the trial’s principal investigator, in Wednesday’s statement. That will be the goal of the research, he said.

Lilly and Roche, based in Basel, Switzerland, have agreed to make their treatments available for the study at no cost, and will support the trial with grants. Another $4.2 million has been given to the investigation from the Alzheimer’s Association, an advocacy group based in Chicago.

The trial will be conducted by Washington University’s unit of the Dominantly Inherited Alzheimer’s Network, or DIAN, an international group of scientists studying rare genetic mutations that cause the disease. The information gathered in these patients may enable better treatment for all dementia patients.

Roche’s gantenerumab binds to clumps of beta amyloid, a protein thought to cause the disease. The drug is thought to help remove the clumps from the brain, and is in a mid- to late-stage company trial that started in 2010. Lilly's solanezumab removes the beta amyloid before it forms plaques.

Another Lilly drug, called a beta secretase inhibitor, is in testing by the company and may be included in the university research as well, according to Wednesday’s statement. That drug is thought to work by reducing the amount of beta amyloid produced in the brain.

The trial, which may start early next year, will test the medicines in inherited early-onset Alzheimer’s patients. The researchers will see if the treatments can prevent the loss of brain function.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. This is still my favorite Mexican restaurant in town. What I do love about the new version is it is much quieter than the most recent version. TV's were off, the music wasn't too loud, and the wait staff were not hyperactive like they had been the past few times I had been there. I just wish they would bring back the MOLE for the enchiladas!

  2. Not a bad paper. There is a need for local community news and city government issues. Don't really need the owner's constant national political rants. We all know where they stand by now.

  3. What nice people. Menard should've known better than to team up with the guy who robbed and drove Conseco to ashes. I'm surprised Timothy Durham isn't involved in this.

  4. Hello, I am Maris Peters, currently living in Texas city, USA. I am a widow at the moment with three kids and i was stuck in a financial situation in August 2014 and i needed to refinance and pay my bills. I tried seeking loans from various loan Companies both private and corporate but never with success, and most banks declined my credit. But as God would have it, I was introduced to a Man of God a private loan lender who gave me a loan of $65,000USD and today am a business owner and my kids are doing well at the moment, if you must contact any firm or company with reference to securing a loan without collateral , no credit check, no co signer with just 2% interest rate and better repayment plans and schedule, please contact Mr William David. He doesn’t know that am doing this but am so happy now and i decided to let people know more about him and also i want God to bless him more.You can contact him through his email: Davidloanfirm@yahoo.com

  5. It is beyond me how anyone can think this was a "bad deal" for the state! If they could take the money back then, yes, but they can't! Protections were built in the agreement. Now, if they roll the roads up and take them away, I will agree that it was a bad deal. Otherwise, the only way to have paid for the infrastructure that was badly needed was for the state to issue bonds....that is a four letter synonym for debt folks!!

ADVERTISEMENT